Cabenuva can replace daily HIV pills with scheduled injections, but its price is enough to make almost anyone inspect an insurance statement with the concentration of a detective studying a suspicious alibi. The good news is that the intimidating list price is often very different from the amount a patient actually pays.
In 2025, the cost of Cabenuva depended on the prescribed dosing schedule, insurance benefits, prior authorization, where the injections were administered, and eligibility for copay or patient assistance programs. This guide explains the numbers, the fine print, and the questions that can prevent an unpleasant billing surprise.
What is Cabenuva?
Cabenuva is a long-acting combination of cabotegravir and rilpivirine. It is administered by a healthcare professional as two intramuscular injections during the same appointment. Depending on the treatment plan, maintenance injections may be given once every month or once every two months.
The FDA-approved regimen is intended to replace a successful antiretroviral regimen in eligible adults and adolescents age 12 or older who weigh at least 77 pounds. Patients generally must already have an undetectable viral load, no history of treatment failure, and no known or suspected resistance to cabotegravir or rilpivirine. It is not an HIV-prevention drug and should not be confused with Apretude, which contains cabotegravir for pre-exposure prophylaxis, or PrEP.
An oral lead-in period using cabotegravir and rilpivirine tablets may be offered to assess tolerability, although it is optional for many patients. The manufacturer’s pricing information states that a 30-day oral lead-in is available at no charge to patients prescribed Cabenuva.
How much did Cabenuva cost in 2025?
There is no single universal Cabenuva price. The manufacturer’s published list-price figures place the smaller 400-mg/600-mg maintenance kit at approximately $4,874 and the larger 600-mg/900-mg kit at approximately $7,311. Each kit contains the two medicines needed for one treatment visit. These are list prices, not guaranteed patient costs.
| Dose kit | Typical use | Approximate list price |
|---|---|---|
| Cabenuva 400 mg/600 mg | Monthly maintenance dosing | $4,874 per kit |
| Cabenuva 600 mg/900 mg | Initiation or every-two-month dosing | $7,311 per kit |
Using those figures, a full year of steady monthly maintenance treatment would have a medication list price of roughly $58,490. Six larger kits used during a steady year of every-two-month treatment would total approximately $43,868. The first year may cost differently because the initiation schedule includes larger doses and depends on when treatment begins.
Independent cash-price databases have shown similar, though not identical, figures. One widely used pricing guide lists cash prices of roughly $4,769 for the four-milliliter kit and $7,150 for the six-milliliter kit. Pharmacy prices can change, and a cash coupon estimate does not guarantee that a clinic or specialty pharmacy can process the discount.
Why the list price is rarely your final bill
The list price is mainly a starting point for negotiations among manufacturers, insurers, pharmacy benefit managers, specialty pharmacies, healthcare systems, and government programs. Your out-of-pocket Cabenuva cost may be a fixed copayment, a percentage-based coinsurance amount, the remaining portion of a deductible, or nothing at all.
In manufacturer-reported specialty pharmacy data covering December 2024 through November 2025, nine out of 10 covered patients paid less than $10 out of pocket per dose after coverage and assistance, and many paid $0. That statistic is encouraging, but it is not a promise. Administration fees and office charges may still apply, and individual insurance designs vary considerably.
What determines your Cabenuva out-of-pocket cost?
Your insurance deductible
A patient who has not met an annual deductible may owe substantially more for an early-year injection than for later appointments. This is one reason a January bill can look like it arrived wearing steel-toed boots, while the same treatment in September may produce a modest copay.
Copayment versus coinsurance
A copayment is usually a fixed amount, such as $25 or $100. Coinsurance is a percentage of the plan-approved cost. Even 10% coinsurance can become expensive when applied to a specialty medication with a four-figure price.
Medical benefit versus pharmacy benefit
Cabenuva can sometimes be covered through the pharmacy benefit and delivered by a specialty pharmacy. In other cases, it is billed under the medical benefit through a “buy-and-bill” arrangement in which the clinic purchases the medication and later bills the insurer.
This distinction matters. A plan may deny Cabenuva under one benefit while covering it under the other. Before treatment begins, ask the clinic to verify both medical and pharmacy benefits. Bring both insurance cards if they are separate.
Prior authorization and formulary rules
Many plans require documentation showing that Cabenuva is medically appropriate. The insurer may request viral-load results, treatment history, resistance information, or confirmation that the patient can attend scheduled injection visits. Prior authorization does not necessarily mean the medication is excluded; it means the paperwork must clear the insurer’s obstacle course first.
The injection location
A hospital-owned outpatient clinic may charge more than an independent HIV clinic, physician office, or approved alternative site of care. Charges can include the medication, injection administration, facility fees, laboratory testing, and the professional visit.
If a plan rejects the current location or applies high coinsurance, ask whether Cabenuva is covered at an alternative site of care. Changing the locationnot the medicationcan sometimes produce the largest savings.
Cabenuva coupons and copay assistance
ViiVConnect Copay Program
Eligible patients with commercial insurance may qualify for the ViiVConnect Copay Program. According to the manufacturer, qualifying patients could pay as little as $0 for prescribed Cabenuva. Program limits, eligibility requirements, insurance rules, and annual maximums apply. It is assistance, not health insurance.
Manufacturer copay cards generally cannot be used by people whose medication is paid for by Medicare, Medicaid, TRICARE, Veterans Affairs benefits, or another federal or state healthcare program. Always review the current terms rather than assuming last year’s enrollment remains active.
Pharmacy discount cards
Consumer prescription websites may advertise Cabenuva coupons or discount-card prices. These cards can be useful for traditional pharmacy prescriptions, but Cabenuva is more complicated because it is administered in a clinical setting and may be obtained through a specialty pharmacy or medical-benefit process.
Before relying on an advertised discount, confirm that the dispensing specialty pharmacy accepts it, that the clinic permits externally supplied medication, and that the quoted price covers the complete kit. A coupon that works beautifully on a website but cannot survive contact with the billing department is not much of a coupon.
ViiV Healthcare Patient Assistance Program
People who are uninsured or have inadequate coverage may qualify to receive eligible ViiV medications at no cost through the manufacturer’s patient assistance program. Income, residency, insurance status, and other requirements apply. A ViiVConnect coordinator can help screen patients and identify the required documents.
Ryan White and ADAP assistance
The Ryan White HIV/AIDS Program supports HIV medical care, medications, and related services for qualifying people with limited income. Its AIDS Drug Assistance Program, commonly called ADAP, provides FDA-approved HIV medications to eligible uninsured and underinsured residents.
Eligibility rules and covered-drug lists are determined by each state or territory, so Cabenuva availability is not identical nationwide. ADAP funds may also help purchase insurance or support services that improve access and adherence. An HIV clinic case manager can often complete the application more quickly than someone attempting to navigate the process alone at midnight with 17 browser tabs open.
How insurance type affects Cabenuva cost
Commercial insurance
Employer and Marketplace plans may cover Cabenuva under the medical benefit, pharmacy benefit, or both. Commercially insured patients are the group most likely to qualify for a manufacturer copay card. The clinic should verify the deductible, coinsurance, preferred specialty pharmacy, administration fee, and site-of-care restrictions before ordering the medication.
Medicare
Medicare coverage can be especially confusing because an injectable medication may fall under different benefits depending on how it is supplied and administered. In 2025, out-of-pocket spending for drugs covered under Medicare Part D was capped at $2,000 for the calendar year. Part D enrollees could also elect to spread covered prescription costs across monthly payments through the Medicare Prescription Payment Plan.
However, the $2,000 Part D cap applied only when a medication was processed as a covered Part D drug. If Cabenuva was billed under a medical benefit instead, different deductibles and coinsurance rules could apply. Patients should ask the plan and clinic which benefit is being used rather than assuming every injectable automatically receives the same treatment.
Medicaid
Medicaid programs differ by state. Coverage may involve prior authorization, managed-care rules, preferred sites, specialty pharmacy requirements, or documentation of clinical eligibility. Manufacturer copay cards are generally unavailable to Medicaid beneficiaries, but state Medicaid coverage, ADAP coordination, or Ryan White services may reduce out-of-pocket expenses.
No insurance
Paying the full Cabenuva cash price is unrealistic for many households. Uninsured patients should contact the manufacturer’s assistance program, a Ryan White-funded clinic, ADAP, a local AIDS service organization, or a certified HIV benefits counselor before concluding that injections are unaffordable. HIV.gov notes that federal programs, patient assistance programs, and copayment support can help eligible uninsured or underinsured patients obtain treatment.
Practical ways to lower Cabenuva costs
- Request a written benefits investigation. Ask for the drug cost, administration charge, deductible status, coinsurance percentage, specialty pharmacy requirement, and approved treatment location.
- Check both insurance benefits. A denial under the pharmacy benefit does not always mean the medical benefit will also deny coverage.
- Enroll in assistance before the first injection. Retroactive reimbursement may be more difficult than arranging support in advance.
- Ask about alternative sites of care. A different clinic or approved injection center may have lower facility charges.
- Use an HIV case manager. Case managers routinely handle prior authorizations, ADAP applications, renewals, appeals, and specialty pharmacy coordination.
- Review coverage every year. Formularies, deductibles, networks, and assistance-program terms can change even when the medication does not.
- Appeal unexpected denials. An initial rejection may result from missing documentation, an incorrect billing code, or use of the wrong insurance benefit.
Questions to ask before starting Cabenuva
- Is Cabenuva covered under my medical benefit, pharmacy benefit, or both?
- Does my plan require prior authorization?
- Which specialty pharmacy must supply the medication?
- What will I owe for the drug and for the appointment?
- Are laboratory tests or facility fees billed separately?
- Can I use the manufacturer copay program?
- Would an alternative injection site cost less?
- What happens to coverage if I travel or change insurance?
Experiences with Cabenuva costs: Four realistic scenarios
The following examples are illustrative composites based on common insurance and access issues. They are not individual medical testimonials, and actual results vary.
Experience 1: The commercially insured patient with a frightening estimate
A patient with employer insurance was initially told that the first Cabenuva visit could cost several thousand dollars. The estimate assumed the medication would be processed through the medical benefit before the deductible was met. After a benefits investigation, the clinic learned that the plan preferred a designated specialty pharmacy.
The medication was transferred to that pharmacy, prior authorization was approved, and the patient enrolled in the manufacturer’s copay program. The final out-of-pocket medication cost was dramatically lower, although a modest office administration charge remained. The lesson was not that every patient will pay nearly nothing. It was that the first estimate may describe the wrong billing pathway rather than the true final cost.
Experience 2: The hidden facility fee
Another patient had excellent drug coverage and expected a small copay. The surprise arrived later as a hospital outpatient facility charge. The medication itself was affordable, but the injection appointment was taking place in a higher-cost hospital-owned department.
The patient asked the insurer whether another approved location was available. Future injections were moved to an independent clinic in the same network. The treatment did not change, but the administration bill did. This experience shows why “How much does Cabenuva cost?” should really be two questions: “How much is the medicine?” and “How much is the visit where I receive it?”
Experience 3: The Medicare coverage puzzle
A Medicare beneficiary heard about the 2025 $2,000 Part D out-of-pocket cap and assumed it would automatically limit all Cabenuva expenses. The clinic discovered that the plan intended to process the medication under a medical benefit rather than Part D.
A benefits counselor reviewed the plan documents, checked supplemental coverage, and coordinated with an HIV case manager. The final arrangement combined insurance benefits with local assistance. The important lesson was that the Part D cap was valuable, but only for medications processed as covered Part D drugs. Confirming the benefit category prevented the patient from building a budget around the wrong rule.
Experience 4: The uninsured patient who assumed treatment was impossible
An uninsured patient saw a retail price above $7,000 and stopped asking questions, believing Cabenuva was automatically out of reach. During a routine HIV clinic visit, a case manager screened the patient for the manufacturer’s patient assistance program and the state ADAP.
The application required income documentation, proof of residency, and clinical information. There were forms, signatures, and enough photocopies to make the office printer reconsider its career choices. Still, the patient ultimately obtained access without paying the list price.
This scenario illustrates why the cash price should not be treated as the end of the conversation. For uninsured and underinsured patients, the most useful “coupon” may not be a printable discount card. It may be a patient assistance program, ADAP enrollment, Ryan White services, or an experienced case manager who knows which door to knock on first.
Experience 5: The cost of scheduling
Cabenuva also carries a practical cost: appointments must occur on schedule. The medication may generally be administered within a limited window around the target treatment date, and planned delays may require temporary oral treatment. A patient with frequent work travel found the every-two-month option easier to manage than monthly visits, but only after confirming clinical suitability with the prescribing provider.
Fewer appointments reduced transportation expenses and missed work hours. However, the larger kit had a higher price per visit, so the patient still needed the clinic to verify coverage for the chosen schedule. Convenience and medication affordability are related, but they are not identical twins.
Safety and scheduling still come before price
Cabenuva can cause injection-site reactions and other side effects. Serious risks may include severe allergic or skin reactions, liver problems, depression, or mood changes. Because the medicines remain in the body for an extended period, missed doses and treatment discontinuation require careful planning. Patients should keep scheduled appointments and promptly discuss delays or side effects with their healthcare team.
Never change the injection schedule, replace Cabenuva with leftover medication, or stop HIV treatment solely because of a bill. Contact the clinic immediately. A billing problem is frustrating; an interruption in an effective antiretroviral regimen can have much more serious consequences.
